 |
 |

HYPERTHYROIDISMTreatment with Radioactive lodine
SERGEI FEITELBERG, M.D.;
PAUL S. KAUNITZ, M.D.;
SOLOMON SILVER, M.D.;
NORMAN SIMON, M.D.;
LOUIS R. WASSERMAN, M.D.;
STEPHEN BENNETT YOHALEM, M.D.
Arch Intern Med. 1950;85(3):471-478.
 |
 |
| Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings. |
|
 |
 |
THE THYROID gland has the ability to concentrate the isotopes of iodine, and this selective uptake is increased greatly in hyperplastic disease of the thyroid gland. Since the initial investigations by Hertz, Roberts and Evans,1 Hamilton and Soley2 and Hertz and others3 there have been numerous reports on the use of radioactive iodine (I130 and I131) in the treatment of patients with hyperthyroidism. The various investigators differ somewhat concerning dosage and the management of their patients, but the basic approach is the same. An initial calculated dose of radioactive iodine is administered orally to the patient, and the majority of investigators prescribe additional therapy as indicated by the subsequent course. Since we studied over 200 patients in the two and a half years previous to this report, we believe it worth while to record our experience.
MATERIAL
The data were sufficiently complete to justify conclusions
. . . [Full Text PDF of this Article]
Author Affiliations
NEW YORK
From the Physics Department and the Medical Services, Mount Sinai Hospital. Dr. Kaunitx is Sara Welt Fellow; Dr. Simon is Dazian Fellow, and Dr. Yohalem is Elsa and William Menke Fellow.
Footnotes
The radioactive iodine (I131) was supplied on allocation by the United States Atomic Energy Commission.
CiteULike Connotea Del.icio.us Digg Reddit Technorati Twitter
What's this?
|